TUHURA BIOSCIENCES INC

NASDAQ: HURA (TuHURA Biosciences, Inc.)

最近更新时间: 15小时之前

1.33

-0.06 (-4.32%)

前收盘价格 1.39
成交量 1,317,162
股市价格/股市净资产 (P/B) 4.84
52周波幅
0.410 (-69%) — 3.43 (157%)
稀释每股收益 (EPS TTM) -0.960
总债务/股东权益 (D/E MRQ) 1.67%
流动比率 (MRQ) 3.00
营业现金流 (OCF TTM) -15.63 M
杠杆自由现金流 (LFCF TTM) -15.19 M
资产报酬率 (ROA TTM) -90.68%
股东权益报酬率 (ROE TTM) -332.67%

AIStockmoo 评分

-2.4
价值 30% -0.5
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
负债低。盈利能力弱。短期流动性充足。现金流为负。 参考
资本回报低于资本成本。资本回报上升。 参考
时机 30% -3.6
来自我们对走势图的 AI 技术分析。 参考 NA
过去一年没有明确趋势。股价远低于52周高点。 参考
K线形态 参考 NA
您持有期的趋势 参考 NA
市场情绪 20% 0.0
近期没有目标价,因此依据目标价的调整方向。 参考
新闻情绪 参考 NA
聪明钱 20% -2.6
内部交易活动 参考 NA
机构在最新13F申报中净-3.16%的股份:25家增持,55家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化-1.0%,回补天数12.6天(FINRA)。 参考
市场和行业状况不佳。
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向一致,评分因此加强。
不计入评分
股价低于其52周平均水平。5年来下跌。 参考
短、中、长期趋势均向下。短期动能下降。 参考
股价接近支撑位。 参考
最终评分 -2.45

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看涨
Biotechnology (全球的) 混合的 看涨
股票 TuHURA Biosciences, Inc. 混合的 看跌

相关股票

股票 市值 DY P/E(TTM) P/B
HURA - - - 4.84
TRML 1 B - - 4.76
TECH - 0.44% - 5.28
MLTX - - - 2.79
VKTX - - - 6.33
VSTM - - - 76.50

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 41.96%
机构持股比例 8.43%

该时间范围内无数据。

该时间范围内无数据。

机构

机构持股比例: 13.83%

持仓变动 机构数 股数
增持 25 1,172,612
减持 55 3,348,265
新建仓 8 600,341
清仓 18 513,423

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 6,203,722 12.6
15 Oct 2026 5,938,259 26.9
30 Sep 2026 6,096,015 28.4
15 Sep 2026 6,279,519 32.6
31 Aug 2026 6,267,797 27.9
14 Aug 2026 6,323,340 21.0

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

0 正面 0 负面 3 中性
日期 类型 细节
13 Nov 2026 Yahoo Finance TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's third quarter ended September 30, 2026, and provided a corporate…
04 Nov 2026 Yahoo Finance TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it would present three posters on its research on the role of the Delta Opioid Receptor (DOR) in…
03 Nov 2026 Yahoo Finance HURA: First Look at IFx-2.0 Deep-Seated Tumors
By John Vandermosten, CFA NASDAQ: HURA READ THE FULL HURA RESEARCH NOTE Interim Readout for IFx-2.0 Phase Ib/IIa Open-Label Study TuHURA (NASDAQ:HURA) presented first data from its IFx-2.0 Phase Ib/IIa study in deep-seated Merkel cell carcinoma (MCC) patients while attending the European Society…
26 Oct 2026 Yahoo Finance TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
TuHURA Biosciences (NASDAQ:HURA) presented preliminary results from its ongoing open-label Phase 1b study of IFx-2.0 in patients with metastatic Merkel cell carcinoma, or MCC, reporting confirmed partial responses in the first three evaluable patients treated in the frontline setting. Speaking duri…
26 Oct 2026 Yahoo Finance TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced initial data from the first three patients in its open-label study of IFx-2.0 as an adjunctive therapy…
13 Oct 2026 Yahoo Finance TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. 12,760,104 entitled…
05 Oct 2026 Yahoo Finance TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,734,168 entitled…
14 Sep 2026 Yahoo Finance TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New…
08 Sep 2026 Yahoo Finance TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C.…
26 Aug 2026 Yahoo Finance HURA: Milestone Progression Over Next 12 Months
By John Vandermosten, CFA NASDAQ: HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On August 14 th , 2026, TuHURA Biosciences, Inc. (NASDAQ: HURA) reported 2Q:26 financial and operational results and filed its Form 10-Q with the SEC. There have been several updates since…

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票